GLOFIL-125: Package Insert and Label Information

GLOFIL-125- iothalamate sodium, i-125 injection
QOL Medical



GLOFIL® -125 (Sodium Iothalamate I-125 Injection) is a sterile, nonpyrogenic aqueous injection containing approximately 1 mg sodium iothalamate per mL, and 0.9 percent benzyl alcohol as a preservative. The radioactive concentration of the material is 250-300 μCi/mL as of the calibration date. Sodium bicarbonate and hydrochloric acid are present for pH adjustment.

Physical Characteristics

Iodine-125 decays by electron capture with a physical half-life of 60.14 days. Photons that are useful for detection are listed in Table 1.

Table 1. Principal Radiation Emission Data *
ICRP Publication 38: Radionuclide Transformations — Energy and Intensity of Emissions. Published for the International Commission on Radiological Protection by Pergamon Press, New York, 1983, p. 446.
Radiation Mean Number Per Disintegration Mean Energy (keV)
Gamma-1 0.067 35.5
1 X-ray 0.741 27.5
2 X-ray 0.398 27.2
1 X-ray 0.140 31.0
2 X-ray 0.043 31.7
3 X-ray 0.072 30.9

The specific gamma ray constant for I-125 is 1.43 R/mCi-hr at 1 cm. The first half value thickness of lead (Pb) for I-125 is 0.017 mm. A range of values for the relative attenuation of the radiation emitted by this radionuclide resulting from interposition of various thicknesses of Pb is shown in Table 2. For example, the use of 0.28 mm of Pb will decrease the external radiation exposure by a factor of 10,000.

Table 2. Radiation Attenuation by Lead Shielding *
Data supplied by Oak Ridge Associated Universities, Radiopharmaceutical Internal Dose Information Center, Oak Ridge, TN 1989.
Shield Thickness (Pb), mm Coefficient of Attenuation
0.017 0.5
0.058 0.1
0.12 0.01
0.2 0.001
0.28 0.0001

To correct for physical decay of this radionuclide, the fractions that remain at selected time intervals after the date of calibration are shown in Table 3.

Table 3. Physical Decay Chart; I-125, half-life 60.14 days
Calibration Date
Days Fraction Remaining Days Fraction Remaining Days Fraction Remaining
0* 1.000 15 0.841 30 0.707
1 0.989 16 0.831 31 0.699
2 0.977 17 0.822 32 0.691
3 0.966 18 0.812 33 0.683
4 0.955 19 0.803 34 0.675
5 0.944 20 0.794 35 0.667
6 0.933 21 0.785 36 0.660
7 0.922 22 0.776 37 0.652
8 0.912 23 0.767 38 0.645
9 0.901 24 0.758 39 0.637
10 0.891 25 0.749 40 0.630
11 0.881 26 0.740 41 0.623
12 0.871 27 0.732 42 0.616
13 0.861 28 0.724 43 0.608
14 0.851 29 0.715 44 0.601
45 0.595


The renal clearance of sodium iothalamate in man closely approximates that of inulin. The compound is cleared by glomerular filtration without tubular secretion or reabsorption. Following infusion administration of I-125 iothalamate, the effective half-life is about 0.07 days.

GLOFIL-125 Indications and Usage

GLOFIL® -125 (Sodium Iothalamate I-125 Injection) is indicated for evaluation of glomerular filtration in the diagnosis or monitoring of patients with renal disease.


GLOFIL® -125 should not be administered via a central venous line.


None known.



As in the use of any radioactive material, care should be taken to minimize radiation exposure to the patient, consistent with proper patient management, and to insure minimum radiation exposure to occupational workers.

Radiopharmaceuticals should be used only by physicians who are qualified by training and experience in the safe use and handling of radionuclides.

Rapid or bolus-like injections should be avoided.

Carcinogenesis, Mutagenesis, Impairment of Fertility

No long-term animal studies have been performed to evaluate carcinogenic potential, mutagenic potential, or whether this drug affects fertility in males or females.

Pregnancy Category C

Animal reproduction studies have not been conducted with GLOFIL® -125. It is also not known whether GLOFIL® -125 can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. GLOFIL® -125 should be given to a pregnant woman only if clearly needed.

Nursing Mothers

Radioiodine is excreted in human milk during lactation. It is not known whether GLOFIL® -125 is excreted in human milk. Therefore, formula feedings should be substituted for breast feedings.

Pediatric Use

Safety and effectiveness in children have not been established.

Adverse Reactions to GLOFIL-125

None reported.



The suggested dose range employed in the average patient (70 kg) is as follows:
Continuous intravenous infusion: 20 to 100 μCi (0.74-3.7 megabecquerels) (Sigman, et al (1) method).
Single intravenous injection: 10 to 30 μCi (0.37-1.11 megabecquerels) (Cohen, et al (2) method).
The patient dose should be measured by a suitable radioactivity calibration system immediately prior to administration.


Continuous intravenous infusion

Sigman (1) method

I. Preparation:

  1. Adequate diuresis (a urine flow exceeding 3 mL/min.) is established, preferably by an oral water load of 1,500 mL two hours prior to the beginning of the clearance study.
  2. It is not necessary to withhold breakfast or admit the patient the night before.

II. Procedure:

  1. After the establishment of adequate diuresis, a number 14 or 16 French Foley catheter is aseptically inserted into the bladder.
  2. An intravenous infusion of Lactated Ringer’s (Hartmann’s) solution is started in each arm, one to maintain a site for injection of the GLOFIL® -125, the other to serve as a site for serial withdrawal of blood. A two-way stopcock connects the needle and intravenous tubing of each arm.
  3. The dose is equally divided into (1) an intravenous priming dose to be injected as is and (2) a sustaining dose to be diluted in 30 to 60 mL of isotonic sodium chloride, depending on how many collection periods are anticipated.
  4. The priming dose is slowly injected into one arm. This is immediately followed by infusion of the sustaining solution through the same site, usually at the rate of 0.5 mL/min., by means of an automatic pump. During this infusion, the Lactated Ringer’s solution in the same arm is discontinued, and 40 to 45 minutes are allowed for equilibration in order to reach a state of constant plasma concentration of radioactivity.
  5. After attaining equilibrium, consecutive 15 minute collection periods are started. From the arm opposite the injection site, 5 mL of blood (allowing duplicate plasma counting volumes) is drawn six minutes prior to the midpoint of each collection period, placed in heparinized tubes, mixed, and centrifuged. The blood samples may be obtained through the two-way stopcock after discarding the first 30 mL aspirated into the syringe. This 30 mL contains the contents of the tubing, including infusion fluid, and must be cleared in order to obtain an undiluted blood sample. If desired, this step may be eliminated and blood samples obtained by direct venipuncture.
  6. During each collection period, total urine must be accurately collected and the volume accurately measured. Three such consecutive collection periods are sufficient for most clinical studies.

III. Clearance Calculations:

  1. Aliquots (1 mL each) of plasma and urine from each collection period are counted in a standard gamma-ray scintillation well detector.
  2. All counts are corrected for background activity.
  3. Glomerular filtration rate is calculated by the formula C=UV/P, in which:
    C = glomerular filtration rate in mL/min
    U= urinary concentration of radioactivity in net counts/min/mL
    V= urinary flow rate in mL/min
    P = plasma concentration of radioactivity in net counts/min/mL
  4. Average glomerular filtration rate (GFR) is calculated from the rates for the individual collection periods. GFR can be expressed in terms of body weight (mL/min/kg) or body surface area (mL/min/m2).
  5. Unilateral glomerular filtration rates can be determined by the same technique by utilizing ureteral catheterization.

Single intravenous injection

Cohen (2) method:

The method of Cohen, et al (2) requires little preparation, few and small blood samples, no bladder catheterization, and no constant intravenous infusion. It is simple to perform, rapid, and utilizes equipment which is readily available in most modern laboratories.

I. Preparation:

  1. Lugol’s solution, 3 drops orally, three times a day, is administered for one or two days prior to the test.

    No diet or water restriction is necessary.

  2. Oral water load is begun one hour before starting the test. Start with 20 mL/kg and force any clear liquids (unless contraindicated) until the test is complete.

II. Procedure: Record actual times for the collection of the blood and urine samples.

  1. Empty the bladder and label the urine Urine control.
  2. Inject 10-30 μCi GLOFIL® -125 intravenously; wait 30 to 60 minutes.
  3. Collect the entire urine and label Urine discard.
  4. Draw 4 to 5 mL of blood into a heparinized syringe. Label Plasma #1.
  5. After another 30 to 60 minutes, collect the entire urine and label Urine #1.
  6. Immediately draw another blood specimen. Label Plasma #2.
  7. After final 30 to 60 minute wait, collect the urine. Label Urine #2.
  8. Draw the last blood specimen immediately. Label Plasma #3.

III. Clearance Calculations:

  1. Radioactivity of one mL aliquots of both urine and plasma are determined using a well-scintillation detector with a single channel pulse-height analyzer. Sufficiently reproducible counts are usually obtained with time settings of 2 minutes for urine samples and 20 minutes for the plasma samples. Calculations of the clearance rates are made by using the formula:(1)

C = UV/P + 1.73/SA where

C = glomerular filtration rate in mL/min/1.73 m2
U = urine radioactivity in counts/min/mL
V = urine flow rate in mL/min
P= mean plasma radioactivity in counts/min/mL
SA= body surface area in m2

Page 1 of 2 1 2 provides trustworthy package insert and label information about marketed drugs as submitted by manufacturers to the US Food and Drug Administration. Package information is not reviewed or updated separately by Every individual package label entry contains a unique identifier which can be used to secure further details directly from the US National Institutes of Health and/or the FDA.

As the leading independent provider of trustworthy medication information, we source our database directly from the FDA's central repository of drug labels and package inserts under the Structured Product Labeling standard. Our material is not intended as a substitute for direct consultation with a qualified health professional.

Terms of Use | Copyright © 2022. All Rights Reserved.